Equities

MannKind Corp

MannKind Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)7.08
  • Today's Change-0.14 / -1.94%
  • Shares traded2.93m
  • 1 Year change+106.41%
  • Beta1.2952
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy2
Outperform2
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 5 analysts offering 12 month price targets for MannKind Corp have a median target of 9.00, with a high estimate of 12.00 and a low estimate of 7.00. The median estimate represents a 27.12% increase from the last price of 7.08.
High69.5%12.00
Med27.1%9.00
Low-1.1%7.00

Earnings history & estimates in USD

On Nov 07, 2024, MannKind Corp reported 3rd quarter 2024 earnings of 0.05 per share. This result was in line with the consensus of the 3 analysts following the company and exceeded last year's 3rd quarter results by 0.04.
The next earnings announcement is expected on Feb 25, 2025.
Average growth rate-100.00%
MannKind Corp reported annual 2023 losses of -0.04 per share on Feb 27, 2024.
Average growth rate+11.98%
More ▼

Revenue history & estimates in USD

MannKind Corporation had 3rd quarter 2024 revenues of 19.73m. This missed the 74.50m consensus estimate of the 3 analysts following the company. This was 51.44% below the prior year's 3rd quarter results.
Average growth rate-9.02%
MannKind Corporation had revenues for the full year 2023 of 198.96m. This was 99.42% above the prior year's results.
Average growth rate+37.70%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.